JP7525855B2 - Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 - Google Patents
Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 Download PDFInfo
- Publication number
- JP7525855B2 JP7525855B2 JP2020557810A JP2020557810A JP7525855B2 JP 7525855 B2 JP7525855 B2 JP 7525855B2 JP 2020557810 A JP2020557810 A JP 2020557810A JP 2020557810 A JP2020557810 A JP 2020557810A JP 7525855 B2 JP7525855 B2 JP 7525855B2
- Authority
- JP
- Japan
- Prior art keywords
- phb2
- peptide
- amino acid
- big3
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024005446A JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018225660 | 2018-11-30 | ||
| JP2018225660 | 2018-11-30 | ||
| PCT/JP2019/046505 WO2020111167A1 (ja) | 2018-11-30 | 2019-11-28 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005446A Division JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020111167A1 JPWO2020111167A1 (ja) | 2021-10-28 |
| JPWO2020111167A5 JPWO2020111167A5 (cg-RX-API-DMAC7.html) | 2022-11-21 |
| JP7525855B2 true JP7525855B2 (ja) | 2024-07-31 |
Family
ID=70853835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557810A Active JP7525855B2 (ja) | 2018-11-30 | 2019-11-28 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
| JP2024005446A Active JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005446A Active JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US12595289B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3889264A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7525855B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020111167A1 (cg-RX-API-DMAC7.html) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013018690A1 (ja) | 2011-07-29 | 2013-02-07 | 国立大学法人徳島大学 | Erap1由来ペプチド及びその使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516611D0 (en) | 1985-07-01 | 1985-08-07 | Du Pont Canada | Fire-retardant sheet material |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB9201180D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| AU7335396A (en) | 1995-11-01 | 1997-05-22 | Dnavec Research Inc. | Membrane-fusible liposome with the use of recombinant sendai virus |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| AU749544B2 (en) | 1998-06-25 | 2002-06-27 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen peptides originating in cyclophilin B |
| US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| JP5339291B2 (ja) | 2006-08-10 | 2013-11-13 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
| JP6923135B2 (ja) | 2016-01-19 | 2021-08-18 | 国立大学法人徳島大学 | がん治療用ペプチド及びそれを含む医薬組成物 |
| CN111148752B (zh) | 2017-07-19 | 2024-01-16 | 国立大学法人德岛大学 | 肽衍生物和包含其的药物组合物 |
-
2019
- 2019-11-28 JP JP2020557810A patent/JP7525855B2/ja active Active
- 2019-11-28 EP EP19890179.5A patent/EP3889264A4/en active Pending
- 2019-11-28 US US17/297,986 patent/US12595289B2/en active Active
- 2019-11-28 WO PCT/JP2019/046505 patent/WO2020111167A1/ja not_active Ceased
-
2024
- 2024-01-17 JP JP2024005446A patent/JP7726464B2/ja active Active
-
2026
- 2026-02-23 US US19/546,921 patent/US20260209292A1/en active Pending
- 2026-02-23 US US19/546,792 patent/US20260234205A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013018690A1 (ja) | 2011-07-29 | 2013-02-07 | 国立大学法人徳島大学 | Erap1由来ペプチド及びその使用 |
Non-Patent Citations (4)
| Title |
|---|
| BMC Research Notes,2014年,Vol.7, No.435,pp.1-8 |
| Cancer Sci.,2015年,Vol.106, No.5,pp.550-558 |
| Nature Communications,2013年,4:2443 |
| 第41回日本分子生物学会年会 要旨集,2018年11月09日,2P-0632 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220098256A1 (en) | 2022-03-31 |
| WO2020111167A1 (ja) | 2020-06-04 |
| JP7726464B2 (ja) | 2025-08-20 |
| US20260209292A1 (en) | 2026-07-23 |
| US12595289B2 (en) | 2026-04-07 |
| EP3889264A1 (en) | 2021-10-06 |
| JPWO2020111167A1 (ja) | 2021-10-28 |
| JP2024045244A (ja) | 2024-04-02 |
| EP3889264A4 (en) | 2022-10-12 |
| US20260234205A1 (en) | 2026-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112119085B (zh) | 稳定肽-介导的靶向蛋白降解 | |
| KR101749204B1 (ko) | 올리고펩타이드 화합물 및 이의 용도 | |
| US11884708B2 (en) | Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs | |
| US20240075099A1 (en) | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | |
| US10087215B2 (en) | Stabilized SOS1 peptides | |
| WO2004092339A2 (en) | Modulation of muc1 mediated signal transduction | |
| US20100292145A1 (en) | Methods of regulating apoptosis | |
| WO2015063747A2 (en) | Peptide inhibitors of tead/yap-taz interaction | |
| WO2013018690A1 (ja) | Erap1由来ペプチド及びその使用 | |
| IL275774A (en) | Variants of ATF5 peptide and their uses | |
| AU2007238186B2 (en) | Disheveled PDZ modulators | |
| JP2024028553A (ja) | Dpep-1結合剤および使用の方法 | |
| CN101146822A (zh) | EphB受体结合肽 | |
| CN115397513A (zh) | 改进的抗衰老化合物及其用途 | |
| JP7726464B2 (ja) | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 | |
| Crnković-Mertens et al. | Isolation of peptides blocking the function of anti-apoptotic Livin protein | |
| Fujiwara et al. | A Cyclized Helix‐Loop‐Helix Peptide as a Molecular Scaffold for Cell‐Membrane Permeable Inhibitors for the Interaction Between Estrogen Receptor α and Coactivator SRC1 | |
| WO2025193770A1 (en) | Macrocyclic peptides | |
| Wen | Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides | |
| Quach | Investigating the Factors that Affect Trafficking of Hydrocarbon-Stapled Peptides and the Epidermal Growth Factor Receptor | |
| Hurd | Development of stapled peptides targeting | |
| Barclay | Direct Inhibition of the Conformational Activation of Pro-Apoptotic BAX by the BH4 Domain Helix of BCL-2 | |
| HK1184473A (en) | Methods and compositions for modulating the wnt pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221110 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230920 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240422 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240424 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240628 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240710 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7525855 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |